PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Reinkemeyer, C.* ; Khazaei, H.* ; Weigert, M.* ; Hannes, M.* ; Le Gleut, R. ; Plank, M.* ; Winter, S.* ; Noreña, I.* ; Meier, T.* ; Xu, L.* ; Rubio-Acero, R.* ; Wiegrebe, S.* ; Le Thi, T.G.* ; Fuchs, C. ; Radon, K.* ; Paunovic, I.* ; Janke, C.* ; Wieser, A.* ; Küchenhoff, H.* ; Hoelscher, M.* ; Castelletti, N.

The prospective COVID-19 post-immunization serological cohort in Munich (KoCo-Impf): Risk factors and determinants of immune response in healthcare workers.

Viruses 15:25 (2023)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Antibody studies analyze immune responses to SARS-CoV-2 vaccination and infection, which is crucial for selecting vaccination strategies. In the KoCo-Impf study, conducted between 16 June and 16 December 2021, 6088 participants aged 18 and above from Munich were recruited to monitor antibodies, particularly in healthcare workers (HCWs) at higher risk of infection. Roche Elecsys® Anti-SARS-CoV-2 assays on dried blood spots were used to detect prior infections (anti-Nucleocapsid antibodies) and to indicate combinations of vaccinations/infections (anti-Spike antibodies). The anti-Spike seroprevalence was 94.7%, whereas, for anti-Nucleocapsid, it was only 6.9%. HCW status and contact with SARS-CoV-2-positive individuals were identified as infection risk factors, while vaccination and current smoking were associated with reduced risk. Older age correlated with higher anti-Nucleocapsid antibody levels, while vaccination and current smoking decreased the response. Vaccination alone or combined with infection led to higher anti-Spike antibody levels. Increasing time since the second vaccination, advancing age, and current smoking reduced the anti-Spike response. The cumulative number of cases in Munich affected the anti-Spike response over time but had no impact on anti-Nucleocapsid antibody development/seropositivity. Due to the significantly higher infection risk faced by HCWs and the limited number of significant risk factors, it is suggested that all HCWs require protection regardless of individual traits.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
4.700
0.000
1
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Covid-19 ; Orchestra ; Sars-cov-2 ; Antibodies ; Breakthrough Infections ; Health Care Workers ; Immunologic Response ; Seroprevalence ; Vaccination
Language english
Publication Year 2023
HGF-reported in Year 2023
ISSN (print) / ISBN 1999-4915
e-ISSN 1999-4915
Journal Viruses
Quellenangaben Volume: 15, Issue: 7, Pages: , Article Number: 25 Supplement: ,
Publisher MDPI
Publishing Place St Alban-anlage 66, Ch-4052 Basel, Switzerland
Reviewing status Peer reviewed
Institute(s) Institute of Radiation Medicine (IRM)
Institute of Computational Biology (ICB)
CF Statistical Consulting (CF-STATCON)
POF-Topic(s) 30203 - Molecular Targets and Therapies
30205 - Bioengineering and Digital Health
30505 - New Technologies for Biomedical Discoveries
Research field(s) Radiation Sciences
Enabling and Novel Technologies
PSP Element(s) G-501391-001
G-503800-001
A-632200-001
Grants European Union
DOI 10.3390/v15071574
WOS ID 001038887600001
Scopus ID 85165941131
PubMed ID 37515259
Erfassungsdatum 2023-10-06
[➜Report correction]